Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

ef="http://www.orexigen.com">www.orexigen.com.

Forward-Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding substantially lower cash expenditures for the second half of 2011 and increased expenditures in 2012, the protocol for, and the timing and feasibility of, the CVOT, the initiation of enrollment for the CVOT in the first half of 2012 and the engagement of a clinical research organization, a clear and feasible path forward for Contrave, and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to come to an agreement with the FDA on the protocol for the CVOT, Orexigen's ability to initiate and conduct the CVOT and the progress and timing thereof, Orexigen's ability to demonstrate in the CVOT that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the CVOT; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resu
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 ... insights on the global resorcinol industry. The report highlights the various growth prospects ... scenarios and analysis of primary and secondary inputs from the existing players of ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... a privately-held company focused on advancing women,s reproductive health, today ... A financing, bringing the total funding to $20 million. The ... the round include Kleiner Perkins Caufield and Byers, TPG Biotech ... the last year, we have executed an aggressive operating plan ...
... 2012   Reportlinker.com announces that a new market ... U.S. Tissue Engineering Markets ... The scope of this research service primarily ... the wound care and surgery space. Surgery ...
... Feb. 1, 2012 Sangamo BioSciences, Inc. (Nasdaq: ... fourth quarter and full year 2011 financial results on Wednesday, ... will be followed by a conference call at 5:00 p.m. ... and webcast. During the conference call, the company will review ...
Cached Biology Technology:Auxogyn Completes $20 Million In Series A Funding 2Auxogyn Completes $20 Million In Series A Funding 3U.S. Tissue Engineering Markets 2U.S. Tissue Engineering Markets 3Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast 2
(Date:7/31/2015)... , July 31, 2015 The 10 th ... held by BGI from October 22-25, 2015, in Shenzhen ... The conference is celebrating its 10 th anniversary this year. ... the world,s most influential annual meetings in the ,omics, fields, ... scientific gatherings. ICG-10 focuses on recent breakthroughs ...
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... a new way of looking beneath the ocean surface ... shrinking. , A remote sensor system developed by Associate ... at MIT, Northeastern University and the Naval Research Laboratory, ... as well as small schools, over a 10,000-square-kilometer area ...
... of Pennsylvania, demonstrate that biodegradable nano-particles containing two ... breast tumors. The unique properties of the ... to deliver two distinct drugs, paclitaxel, the leading ... Taxol, and doxorubicin directly to tumors implanted in ...
... have found a way to keep a protein "watchdog" on ... - if they can keep it on a leash of ... team of scientists including Purdue University's Susan M. Mendrysa has ... has the ability to halt the progression of intestinal tumors ...
Cached Biology News:One fish, two fish: New MIT sensor improves fish counts 2Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2Loosen leash on cancer protein 'watchdog,' researchers say 2Loosen leash on cancer protein 'watchdog,' researchers say 3Loosen leash on cancer protein 'watchdog,' researchers say 4
IEX-1 S/L (H-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
VAP-1 (S-13)...
Biology Products: